BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23065990)

  • 21. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
    Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
    Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B: explosion of new knowledge.
    Keeffe EB
    Gastroenterology; 2007 Nov; 133(5):1718-21. PubMed ID: 17983813
    [No Abstract]   [Full Text] [Related]  

  • 23. [The past, present and future treatment for chronic hepatitis B].
    Okanoue T; Minami M
    Nihon Rinsho; 2011 May; 69 Suppl 4():469-74. PubMed ID: 22096963
    [No Abstract]   [Full Text] [Related]  

  • 24. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
    Salpini R; Alteri C; Cento V; Pollicita M; Micheli V; Gubertini G; De Sanctis GM; Visca M; Romano S; Sarrecchia C; Andreoni M; Angelico M; Parruti G; Svicher V; Perno CF
    J Med Virol; 2013 Jun; 85(6):996-1004. PubMed ID: 23588725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analogs and fibrosis regression in hepatitis B.
    Bourlière M; Kahloun A; Gascou-Tessonnier G
    Gastroenterol Clin Biol; 2009; 33(10-11):923-9. PubMed ID: 19640665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
    Yap DY; Tang CS; Yung S; Choy BY; Yuen MF; Chan TM
    Transplantation; 2010 Aug; 90(3):325-30. PubMed ID: 20562676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic hepatitis B with advanced fibrosis or cirrhosis: impact of antiviral therapy.
    Arora G; Keeffe EB
    Rev Gastroenterol Disord; 2007; 7(2):63-73. PubMed ID: 17597674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides.
    Nguyen MH; Keeffe EB
    J Viral Hepat; 2009 Mar; 16(3):149-55. PubMed ID: 19236641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
    Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Managing resistance to analogue antiviral drugs in a decompensated cirrhosis patient].
    Zarski JP
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S20-1. PubMed ID: 17075491
    [No Abstract]   [Full Text] [Related]  

  • 32. New treatment of chronic hepatitis B.
    Lok AS
    Semin Liver Dis; 2004; 24 Suppl 1():77-82. PubMed ID: 15192805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A study on the treatment of chronic hepatitis B with YMDD mutation].
    Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Influence of nucleoside analogues resistance on anti-HBV treatment].
    Hou JL; Sun J
    Zhonghua Yi Xue Za Zhi; 2005 May; 85(17):1156-7. PubMed ID: 16029585
    [No Abstract]   [Full Text] [Related]  

  • 35. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
    Chu M; Cho SM; Choe BH; Cho MH; Kwon S; Lee WK
    J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):648-52. PubMed ID: 22688509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.
    Chien RN
    J Gastroenterol Hepatol; 2010 May; 25(5):852-7. PubMed ID: 20546437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral options for the treatment of chronic hepatitis B.
    Osborn MK; Lok AS
    J Antimicrob Chemother; 2006 Jun; 57(6):1030-4. PubMed ID: 16595637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute liver failure resulting from discontinuation of nucleoside analogues in chronic hepatitis B patients: a report of two cases.
    Wang J; Wang M; Huang Y
    Scand J Infect Dis; 2013 Feb; 45(2):158-60. PubMed ID: 22830672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
    Leung N
    Liver Int; 2011 Jan; 31 Suppl 1():85-9. PubMed ID: 21205143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.